Asundexian did not raise major bleeding after stroke, but gut bleeds rose

Adding the experimental clot-blocker asundexian to standard antiplatelet therapy did not significantly increase major bleeding in people who had just had a stroke or a high-risk warning stroke, according to a detailed safety analysis of the large OCEANIC-STROKE trial [s1]. The one exception was bleeding lower in the gut, which was more common on the drug — a nuance that matters for a medicine whose entire appeal rests on separating clot protection from bleeding risk [s1].

Asundexian belongs to a closely watched new class of anticoagulants that block factor XI, a protein in the clotting cascade. The hope behind the class is that factor XI is more important for forming dangerous clots than for the everyday clotting that stops bleeding, so blocking it might prevent strokes and heart attacks without the bleeding penalty that limits older blood thinners [s1]. The parent OCEANIC-STROKE trial tested that idea in secondary stroke prevention, and its headline result was that asundexian added to antiplatelet therapy reduced ischaemic stroke without a significant rise in bleeding [s1]. The analysis reported here dissects that bleeding safety record in detail.

What the analysis did

OCEANIC-STROKE enrolled patients with a recent non-cardioembolic ischaemic stroke — one not caused by a clot thrown from the heart — or a high-risk transient ischaemic attack, the brief "warning" strokes that often precede a larger one [s1]. The safety population comprised 12,254 participants who received at least one dose, split almost evenly between asundexian (6,124) and placebo (6,130) [s1]. The trial is registered as NCT05686070 and is now complete [s2].

Investigators classified every bleed using the International Society on Thrombosis and Haemostasis criteria as major, clinically relevant non-major (CRNM), or minor, and analysed events while patients were on treatment, counting death and permanent discontinuation as competing risks [s1].

What it found

Major bleeding occurred in 117 patients (1.9%) on asundexian and 107 (1.7%) on placebo — a cause-specific hazard ratio of 1.10, with a 95% confidence interval of 0.85 to 1.44 and a P value of 0.46, meaning no significant difference [s1]. Widening the net to major or CRNM bleeding gave 339 events (5.5%) versus 307 (5.0%), hazard ratio 1.12 (95% CI 0.96 to 1.30; P=0.16), and any bleeding at all affected 763 patients (12.5%) against 752 (12.3%), hazard ratio 1.02 (95% CI 0.93 to 1.13; P=0.65) [s1]. Symptomatic bleeding into the brain — the most feared complication after a stroke — occurred in 41 patients (0.7%) on the drug and 36 (0.6%) on placebo [s1].

The signal was in the gut. Any gastrointestinal bleeding occurred in 186 patients (3.0%) on asundexian versus 147 (2.4%) on placebo, a hazard ratio of 1.28 (95% CI 1.03 to 1.59), and lower gastrointestinal bleeding — chiefly rectal — occurred in 102 patients (1.7%) against 59 (1.0%), hazard ratio 1.75 (95% CI 1.27 to 2.41) [s1]. Treatment effects on major and on major-or-CRNM bleeding were consistent across prespecified subgroups, including patients who were also taking two antiplatelet drugs [s1].

How to read it

This is a reassuring safety picture with one asterisk. On the headline measures that drive clinical decisions — major bleeding, intracranial bleeding, any bleeding — asundexian looked no different from placebo, and the confidence intervals comfortably crossed one [s1]. That is the result the factor XI hypothesis predicts, and it held even in the higher-risk group on dual antiplatelet therapy [s1].

The lower-gut bleeding finding is the honest counterweight. Both its confidence intervals sat above one, so it is unlikely to be chance, and it is a reminder that "does not increase bleeding overall" is not the same as "does not increase any bleeding anywhere" [s1]. For most patients a rise in rectal bleeding is far less consequential than a brain bleed, but it is the kind of effect that can drive people to stop taking a drug and that warrants investigation at follow-up. For how a related factor XI inhibitor fared in a different setting, see our coverage of milvexian in acute coronary syndromes, and for device-based stroke prevention, catheter ablation to prevent stroke.

What to watch

The practical question for this class is whether the clot-protection benefit is large enough, and the bleeding penalty small enough, to change secondary stroke prevention — a field long dominated by aspirin-based regimens [s1]. This analysis strengthens the safety side of that ledger while flagging the gut as the place to watch. How regulators and guideline writers weigh a reduced stroke rate against a measurable rise in lower gastrointestinal bleeding will shape where asundexian lands [s1][s2].

This article describes research and is not medical advice. Decisions about stroke prevention are for patients and their clinicians.